Oruka Therapeutics, Inc. — Director's Dealing 2012

Oct 25, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARCA biopharma, Inc. (ABIO)
CIK: 0000907654
Period of Report: 2012-10-22

Reporting Person: ZABRISKIE JOHN L (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-10-22	Common Stock	A	126951	$.3939	Acquired	156131	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-10-22	Common Stock Warrants (right to buy)	$.3001	A	95213	Acquired	2017-10-25	Common Stock (95213)	Indirect

Footnotes

F1: These shares are owned directly by Lansing Brown Investments, LLC. Dr. Zabriskie, one of ARCA's current directors, is the President of Lansing Brown Investments, LLC. Dr. Zabriskie has shared voting and dispositive powers over the shares held by Lansing Brown Investments, LLC. He disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in them.

F2: The warrants are fully vested and exercisable upon issuance and have a contractual term of 5 years.